

Index

- Acetylcholine 131-132
- Actin 4, 207-208
- Adenine nucleotides
 - and adrenergic nerves 177-179
 - and adrenergic neurotransmission 176-177
- Adenosine 178
- Adenylate cyclase 81
- ADP 160
- ADP-ribosylation 80-83
 - pertussis-toxin-catalysed 84
- Adrenal chromaffin cell 191-218
- Adrenergic neuroeffector interaction 160
- Ageing 31
- 1-*O*-alkyl-phosphatidylcholine 50-51, 59
- Alprazolam 269, 274
- Alz-50 23
- Alzheimer's disease 23-24
- Amino acids, excitatory 21
- Angiotensin II 53, 57-58, 68
- Angiotensin II receptors 57-58
- Annexins 198
- Anxiety 267, 279
- Aplysia*, bag cell neurons of 116-121, 135
- Arachidonic acid 197
- Aspartate 132
- Astrocytoma cells 53, 61-62
- Atherosclerosis 164
- ATP 53, 62-63, 160, 200-202
 - as co-transmitter 177
- Axonal degeneration 25
- Axonal differentiation 36

- Bacterial toxins 80, 84
- Bag cell neurons, of *Aplysia* 116-118
- Barbiturate sites 264
- Benzodiazepine agonists 264, 267-270
- Benzodiazepine receptors 260
 - peripheral 260
 - selective ligands for 259-293
- Benzodiazepines
 - endogenous 282-283
 - new 265
- Binding *in vivo* 270-271, 277-279
- Biomembranes 50
- Botulinum toxin 206-207
- Bradykinin 53, 58
- Bradykinin receptors 58

- CA1 region, of hippocampus 27
- Ca²⁺-ATPase 196
- Caffeine 195
- Calcineurin 201
- Calciosome 196
- Calcium 7, 21, 36, 40, 81
 - and arachidonic acid 197
 - direct actions of 197
 - and neurodegeneration 21-23
- Calcium buffering 33
- Calcium channels 10, 100, 111, 116-126, 131, 135
 - in *Aplysia* neurons 116, 121, 126, 135
 - L-type 121-126
 - N-type 121-125
 - protein kinase C-induced 116-126
 - T-type 121-124
 - voltage-dependent 35
- Calcium ionophore 9
- Calcium pumps 33
- Calcium/calmodulin-dependent protein kinase 110-111, 114
- Calcium-dependent proteinases 22
- Calcium-induced calcium release 196
- Caldesmon 209
- Calmodulin 13, 199-200
- Calmodulin kinase 199
- Calpactin 198
- cAMP, *see* Cyclic AMP

- α -Carbolines 260-261, 266, 269-270, 272-273, 275, 279
- Catecholamines 180
- α -CCE 280, 282
- Cellular signalling 30
 - imbalances in 30-32
- Cerebral arteries 166
- c-fos* gene 143, 147, 149-153
- cGMP, *see* Cyclic GMP
- CGS 8216 280-281
- CGS 9896 276
- Chemotactic peptide 53, 59-60
- Chemotactic peptide receptors 59-60
- Chimeric proteins 103
- Chloride channels, voltage
 - dependent 130-131, 135
- Chloride flux 263, 274, 280
- Cholecystokinin 53, 58, 68
- Cholecystokinin receptors 58
- Cholera toxin 205
- Choline 52, 54, 61-62
 - as the precursor of acetylcholine 69
- Choline phospholipids 49-76
 - fatty acid composition of 54
 - hydrolysis of 52-56
 - calcium-dependence of 55, 66
 - phosphoinositide (PI) breakdown and 56
 - protein kinase C and 56, 67
 - receptor-mediated 53, 56-64
 - receptor-coupled hydrolysis of 52-56
 - receptors and stimuli linked to 56-64
 - water-soluble metabolites of 52, 54
- c-jun* gene 151
- CL 218,872 270, 272
- Clobazam 270
- α -CMC 275-276
- CNS ischaemia, ENK and NPY
 - responses to 247-249
- Co-localization 220, 235, 237
- Co-release, evidence for 246-249
- Co-storage 168, 220-221
- Crystal structure 79
- α -CtB 277
- Cyclic AMP (cAMP) 14-15, 110, 115, 118, 120, 127, 204
- Cyclic GMP (cGMP) 204
- Cyclic nucleotides 204
- Cytoskeleton 2, 207-209
- Cytosolic calcium [Ca^{2+}]_i 193-196
- Cytosolic pH 210
- DAG, *see* Diacylglycerol
- DBI 282
- Development 16, 26, 31, 90
- Diacylglycerol 52, 54, 64, 66-68, 110-115, 118, 123-125, 128, 133, 202
 - formation of 112-113
 - synthetic 114, 118, 123-125, 128
- Diazepam 260
- Differential exocytosis 239-243
 - electron microscopy 242
 - LDVs 239-251
 - SVs 239-245
 - vesicle 228
- Differentiation 19
- Dihydropyridines 111, 122, 125
- Dilatation 182
- 2-Dimensional electrophoresis 90
- DMCM 266, 273, 279-280
- Dopamine 132, 153
- Dopamine α -hydroxylase 233-234
- Dorsal root ganglion 121-125
- Drosophila* 103
- Dysautonomia 252
- EDRF 164-165
- Eicosanoids 113
- Electron-transfer proteins, function
 - of 251
- Elongation factors 79
- Endogenous benzodiazepines 282-283
- Endogenous ligands 278, 281-283
- Endoperoxide shunting 175
- Endothelial cells 53, 58
- Endothelium 161
- Endothelium removal 171
- Endothelium-dependent relaxation 164
- Endothelium-derived relaxing factor, *see* EDRF
- Enkephalin content, of the pig 221
- Enkephalins, processing and synthesis
 - of 247
- Entorhinal cortex 18
- Epilepsy 135
- Excitatory amino acid 21
- Excitotoxicity 28
- Exocytosis 169-210, 219-258
 - and the calcium signal 193-196
 - control of, in secretory cells 191-218
 - differential 239-243
 - functional 223
 - mechanism of 196-210
 - omnidirectional 229
 - osmotic driving forces in 210
 - vesicle 222, 227
 - demonstrated by electron microscopy 222

- Fatty acids 113
 FG 7142 266, 273, 279-280
 Fibroblast 3T3-L1 53, 58-59
 Fibroblast growth factor 3
 Filopodia 5
 Flumazenil 260, 273-274, 276-278, 281
 fMet-Leu-Phe, *see* Chemotactic peptide
 Fodrin 208
 Forskolin 14
 Fucose-sulphate-glycoconjugate 53, 63-64
 Functional co-storage, ideal criteria for 249-250
 Fura-2 10

 GABA 15, 132, 263, 267, 274
 GABA_A 110, 131
 Gangliosides 114
 GAP-43 37, 111, 132-133
 G_e 205
 Gelsolin 209
 Gene expression 41
 Glioma 88
 Glutamate 10, 132
 Glutamate receptors 17
 Glycerophospholipids 50-52
 Glycine 274
 GMP.PNP 205
 Gonadotrophin releasing hormone 53, 60-61
 Gonadotrophin releasing hormone receptors 60-61
 G-protein mutants 93
 G-proteins 32, 80-104
 isolation of mutants 103-104
 pertussis-toxin-sensitive 80-102
 immunological identification of 87-92
 and ion channels 99-102
 physical location of 97-99
 Granulocyte (HL-60) 53, 59-60
 Growth cone motility 8
 Growth cones 4, 37
 GTP analogues 82
 GTPase activity 95
 GTP-binding proteins 77-107, 112, 124
 GTP- γ -S 205
 Guanine-nucleotide-binding proteins 204-206

Ha-ras oncogenes 53, 64
 Hemostasis 164
 Hepatocyte 53, 57, 62
 12-HETE 174

 High performance ion exchange chromatography 90
 Hippocampus 4, 125, 127-129, 132-133, 135
 CA1 region of 27
 12-HPETE 174
 5-HT 132, 160, 165-173
 activity at prejunctional receptors 168-171
 release of, from vascular adrenergic nerves 167-168
 uptake of 163
 in vascular adrenergic nerves 166-167
 5-HT₁ receptors 168
 5-HT₃ receptors 170
 Hybridization *in situ* 91
 5-Hydroxytryptamine, *see* 5-HT
 Hypnotics 261, 271

 Immunocytochemistry 91
 Immunogold labelling 239-240
 Inositol-1,4,5-triphosphate 112-113, 118, 129-130
 Inositol phospholipid metabolites 13-14
 Inositol phospholipids 13
 Insulin 53, 60
 Insulin receptors 60
 Interleukin 1 53, 58-59
 Interleukin 1 receptors 58-59
 Intermediate-early genes, in alterations of the CNS 143-157
 Intracellular signalling 15
 Inverse agonists 261, 278-281
 Ion channels 33
 IP3 195-196

 K⁺ channels 99
 Kinases 13
 Kindling 143, 149, 273

 Large dense vesicles, transmitter 'poor' 246, 251
 LDVs, *see* Large dense vesicles
 Leukocyte 53, 59-60
 LHRH, *see* Luteinizing-hormone-releasing hormone
 Ligand-regulated ion channels 110-111, 131
 Lipid bilayer 50
 Lipocortin 64
 Lipoxin A 113
 Lipxygenase 173
 Lorazepam 269, 283

- Luteinizing-hormone-releasing hormone (LHRH) 129, 132
- Memory 145
- Metalloendoproteases 209-210
- Metalloproteases 209-210
- Microfilaments 2
- Microtubule-associated proteins 35
- Microtubules 78
- Mitotic sister neurons 26
- Monoamine oxidase 164
- Muscarinic acetylcholine receptors 93, 127, 129
- Muscarinic receptor agonist 53, 61-62
positive inotropic effect 68-69
- Muscarinic receptors 61-62, 194
- Mutagenesis, site-directed 103
- Myocyte (BC3H-1) 53
- NAD-glycohydrolase 84
- Negative feedback control 178
- Nerve growth factor 3
- Neural plasticity 143, 149
- Neurite elongation 8
- Neurite outgrowth 7
- Neuroarchitecture, molecular regulation of 41
- Neuroblastoma cells 53, 61-62, 80
- Neurodegeneration 30
and calcium 21-23
calcium-independent 23-26
role of second messengers in 26-30
- Neurodegenerative disorders 26, 40
- Neuronal cell culture 6
- Neuronal degeneration 20
- Neuronal growth and degeneration, second messengers in 1-48
- Neuronal plasticity 115, 132-135
- Neuronal polarity 36
- Neurons
bag cell, of *Aplysia* 116-118
mitotic sister 26
noradrenergic 224-235
concepts of 224
pyramidal 17
selective death of 26
- Neuropathology 22
- Neuropeptide co-localization 235-238
- Neuropeptide co-storage 219-258
in purified vesicle fractions 243-246
and ultrastructural immunogold labelling 239
- Neuropeptide Y 124, 181-182, 221, 245
- Neuropeptides 219
processing of 250-252
- Neurotoxicity 21
- Neurotransmitter release 110, 116-117, 121, 126, 131, 135
- Neutrophil, *see* Leukocyte
- NGFI-A (zif/268) 143, 147, 159
- Nicotinic acetylcholine receptor 110-111, 131
- Nicotinic receptor 192
- NIH/3T3 cell 53, 64
- NMDA 16
- NMDA receptors 152
- Noradrenaline 160
release of 169
- Noradrenaline concentration
gradient 232
- Noradrenaline synthesis, by LDVs 232-235
- Noradrenaline synthesis complex 231
- Noradrenaline uptake complex 231
- Noradrenergic neurons 224-235
contents of 225-226
transport of 224-226
- Norepinephrine 123-124, 132
- NPY, *see* Neuropeptide Y
- Oncogenes 146-147
activation of, in cultured cells 147-149
- Opioid receptors 84
- Osmolarity 210
- Osmotic shock 25
- Ovarian granulosa cell 53, 60-61
- P21 *n-ras* 79-80
- Pancreatic acinar cell 53, 58
- Partial agonists 267, 274-277
- Peptide receptors 53, 57-61
- Peripheral benzodiazepine receptors 260
- Permeabilized cells 192, 194
digitonin 192, 194
electrical 192, 194
staphylococcal α -toxin 192, 194
streptolysin-O 192, 194
- Pertussis toxin 205
- PET studies 277
- Phorbol esters 91
- Phosphatidic acid 54, 64-65, 68-69
- Phosphatidic acid
phosphohydrolase 57, 64-67
inhibition by propranolol 65
- Phosphatidylethanol 57, 59, 61-67

- Phosphatidylinositol 4,5-bisphosphate (PIP₂)
 protein kinase C 67
 receptor-mediated hydrolysis of 51, 53, 67
- Phospholipase
 distribution and localization of 65-66
 role in signal transduction 66-69
 transphosphatidylation reaction, *see* Phosphatidylethanol
- Phospholipase A₂ 78, 112-113, 197
- Phospholipase C 112-113, 125, 202-203
- Phospholipase D 49-76
- Phospholipases 50-52, 66
- Phospholipid-binding proteins, Ca²⁺-dependent 198-199
- Phospholipids 110-113
- Phosphorylation 200-202
- PK 8165 276
- PKC, *see* Protein kinase C
- PLA₂, *see* Phospholipase A₂
- Plasticity 31
- Platelet aggregation 161
- Platelet release reaction 161-162
- Platelet-activating factor 181
- Platelet-derived 5-HT 171
- Platelet-derived growth factor 53, 59
- Platelet-derived growth factor receptor 59
- Platelet-derived nucleotides 179
- Platelet-derived products
 and adrenergic nerve terminals 165-182
 and adrenergic transmission 159-190
- Platelet-derived substances, and vascular reactivity 162-165
- Platelets 53, 63, 160
- PLC, *see* Phospholipase C
- Potassium channels 113, 116, 118-119, 123, 126-131, 135
 A current (I_A) 126, 130, 135
 after-hyperpolarization current (I_{AHP}) 127-130, 135
 calcium-dependent 113, 119, 126-128, 130
 delayed rectifier (I_{KV}) 126, 130
 M current (I_M) 129-130, 135
- Prejunctional receptors 168
- Presynaptic receptors 275
- Presynaptic terminals 19
- Propranolol 65
- Prostaglandin endoperoxides 161
- Prostaglandins 174
- Protein kinase C 13, 56, 66-68, 109-135, 202-203
 activators of 110-135
 cellular regulation of 111-114
 down-regulation of 124, 132
 inhibitors of 113-115, 118-120, 123, 125, 128, 131-134
 isozymes of 110-111, 134
 in long-term potentiation of synaptic efficacy 132-134
 modulation of potassium conductances by 126-131
 persistent activation of 115-116, 121, 133-134
 properties and regulation of 110-116
 and regulation of ion channels and neurotransmitter release 109-142
 in regulation of neurotransmitter release 131-132
 substrates of 111, 122, 130-133
 translocation of 111, 114-115, 133
- Proteinases, calcium-dependent 22
- Proto-oncogenes 146-147
- Purified vesicles
 and electron microscopy 244
 neuropeptide content of 243
 neuropeptide co-storage in 243-246
- Purinergic receptors 62-63, 177
see also ATP
- Pyramidal neurons 17
- Ras* 206
- Receptors 34
 thromboxane 173
- Reserpine
 in antihypertensive therapy 252
 ENK and NPY responses to 247-249
- Ro 15-4513 260, 280
- Ro 19-4603 280
- S49 lymphoma 81
- Schizophrenia 143
- SEC4 206
- Second messengers 5, 31, 41
 in neuronal growth and degeneration 1-48
 and therapeutic strategies for neurodegenerative disorders 40
- Seizures 149, 267, 279-281
- Selective cell death 28
- Serotonin, *see* 5-HT
- Signal transduction 32
- Site-directed mutagenesis 102
- Sodium channels, voltage dependent 111, 130

- Sodium/calcium exchange 28
 SP, *see* Substance P
 Spermatozoon 53, 63
 Sphingolipids 113-114, 118, 133
 Spreading depression 152
 SR 95195 280
 Substance P 124, 129, 246
 in serotonergic LDVs 246
 Sulphatides 113
 Sympathetic nervous system 160
 Synaptogenesis 17
 and second messengers 17-20
 Synexin 198

 Tau 23
 Tetanus toxin 206-207
 Tetrazepam 270
 Theophylline 179
 Thrombin 53, 63
 Thrombin receptors 63
 Thromboxane A₂ 160
 and endoperoxides 173-174
 and noradrenaline release 174-176
 Thromboxane B₂ 176
 Thromboxane receptor antagonists 176
 Thromboxane receptors 173
 Thromboxane synthetase inhibitors 176
 T-lymphocytes 53, 58-59
 Transfer proteins, e⁻ 251

 Tribulin 282
 Tubulin 4
 Type 1 and type 2 receptors 270-271,
 275-276

 U46619 175

 Vasopressin 53, 57, 180-181
 Vasopressin receptors 57
 Vesicle co-storage, by immunogold
 labelling 239-240
 Vesicle exocytosis 222
 Vesicle formation 225-226
 Vesicle markers 251
 Vesicle pore formation 229
 Vesicle recycling 230
 Vesicle storage 232
 Vesicles 223
 large dense cored 245
 VIP 245
 Voltage-dependent calcium
 channels 35, 193

Xenopus oocytes 125, 130-131

 ZK 91296 276
 ZK 93426 273, 276-278
 Zolpidem 271